Nomination of François Boutignon as Chief Innovation and Technology Officer

CPhIworldwide Milan

CPhI Worldwide 2021 in Milan

Vectans Pharma will be present at the CPhI worldwide in Milan from November 9 to 11, 2021.

OTC switch approval for SitavigFrance

OTC switch approval for Sitavig® 50 mg in France

Vectans pharma is proud to announce that its one-per-episode Lauriad® aciclovir treatment tablet for herpes labialis, Sitavig® 50mg, has received the approbation of the ANSM for OTC commercialization in France. Issued from Lauriad technology, SITAVIG ensures an optimum and efficient localized concentration of acyclovir directly at the disease site.
A big step for Vectans , but also for the many patients in France prone to recurrent

Lauriad technology

Lauriad® technology in pictures

Because changing the way medicines are delivered can improve patient’s life drastically. With Lauriad® we are committed to optimizing the existing therapeutic offer, bringing out new « best-in-disease » drugs.


China approves commercialization for Oravig®

China's NMPA authorization

China approves authorization of commercialization for Oravig®


Happy New Year!

In 2021, Vectans Pharma will offer new therapeutic perspectives based on Lauriad® technology.


LORAMYC® 50 mg in Germany

Vectans Pharma is glad to inform you that BfArM granted a 3-year exemption of the sunset clause for LORAMYC® 50 mg, a muco‐adhesive buccal tablets issued from the Lauriad Technology, an innovative and patented drug delivery system ensuring targeted diffusion of Miconazole. In addition to Germany, LORAMYC® is also registered in other European countries such as the United Kingdom, France and Italy. LORAMYC® also benefits from an international presence through international licensing agreements in the United States and Asian countries.

Visuel 2

Exclusive licensing agreement with m8 Pharmaceuticals

Exclusive licensing agreement with m8 Pharmaceuticals

230 Bureaux de la colline
92213 Saint-Cloud